30 Day Trial

Study results: Episealer may stop or significantly slow the process leading to OA


Study results suggest that a permanent bond may form between cartilage and the hydroxyapatite coating of Episurf's Episealer® device, suggesting that implantation may stop or significantly slow the process leading to OA. This is reported to be the first time that such results have been shown.

Results of the sheep study are accepted for the ESSKA 2016 meeting in Barcelona, Spain.

Source: Episurf Medical

Episealer personalized implants and Epiguide® surgical drill guides intended to treat localized cartilage injury in joints, specifically the knee. Episurf received its first CE Mark approval in 2013, and has since continued to receive the regulatory approval across its product line. Its most recent CE Mark approval was secured for the Epioscopy™ Damage Assessment Tool.

For the first 9 months of 2015, Episurf Medical posted sales of SEK 641,094 (~$74,200), +441% vs. the prior year. The company is slated to announce full-year results on 2/23/16.